UA107180C2 - Туберкульозний білок rv1753c, композиція, що його містить, та застосування - Google Patents

Туберкульозний білок rv1753c, композиція, що його містить, та застосування

Info

Publication number
UA107180C2
UA107180C2 UAA201100362A UAA201100362A UA107180C2 UA 107180 C2 UA107180 C2 UA 107180C2 UA A201100362 A UAA201100362 A UA A201100362A UA A201100362 A UAA201100362 A UA A201100362A UA 107180 C2 UA107180 C2 UA 107180C2
Authority
UA
Ukraine
Prior art keywords
rv1753c
administration
composition containing
tuberculosis protein
rvl753c
Prior art date
Application number
UAA201100362A
Other languages
English (en)
Russian (ru)
Inventor
Джеймс Браун
Паскаль Меттенс
Денніс Мюрфі
Original Assignee
Глаксосмітклайн Байолоджікалз С.А.
Глаксо Груп Лімітед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксосмітклайн Байолоджікалз С.А., Глаксо Груп Лімітед filed Critical Глаксосмітклайн Байолоджікалз С.А.
Publication of UA107180C2 publication Critical patent/UA107180C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)

Abstract

Винахід стосується застосування поліпептиду, який містить: (і) білок Rv1753c послідовності SEQ ID NО: 1 або 3-7; або (іі) варіант білка Rv1753c послідовності, що має принаймні 90 % ідентичності з SEQ ID NО: 1, або (ііі) імуногенний фрагмент, що містить принаймні 10 амінокислотних залишків з білка Rv1753c послідовності SEQ ID NО: 1, у виробництві лікарського засобу для лікування або запобігання туберкульозу, полінуклеотиду, який включає послідовність нуклеїнової кислоти, що кодує вказаний поліпептид, та способів лікування або запобігання туберкульозу.
UAA201100362A 2008-07-25 2009-07-24 Туберкульозний білок rv1753c, композиція, що його містить, та застосування UA107180C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8369208P 2008-07-25 2008-07-25
PCT/EP2009/059586 WO2010010180A1 (en) 2008-07-25 2009-07-24 Novel compositions and methods

Publications (1)

Publication Number Publication Date
UA107180C2 true UA107180C2 (uk) 2014-12-10

Family

ID=41172233

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201100362A UA107180C2 (uk) 2008-07-25 2009-07-24 Туберкульозний білок rv1753c, композиція, що його містить, та застосування

Country Status (24)

Country Link
US (2) US9315556B2 (uk)
EP (1) EP2315597B1 (uk)
JP (1) JP5824360B2 (uk)
KR (2) KR20160013262A (uk)
CN (2) CN102164612B (uk)
AU (1) AU2009273133B2 (uk)
BR (1) BRPI0916705A2 (uk)
CA (1) CA2731549C (uk)
CO (1) CO6400198A2 (uk)
CY (1) CY1119737T1 (uk)
EA (1) EA022203B1 (uk)
ES (1) ES2647321T3 (uk)
HR (1) HRP20171694T1 (uk)
HU (1) HUE037121T2 (uk)
IL (1) IL210588A0 (uk)
LT (1) LT2315597T (uk)
MX (1) MX2011000981A (uk)
NO (1) NO2315597T3 (uk)
PL (1) PL2315597T3 (uk)
PT (1) PT2315597T (uk)
SG (1) SG10201505149WA (uk)
SI (1) SI2315597T1 (uk)
UA (1) UA107180C2 (uk)
WO (1) WO2010010180A1 (uk)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2315834B1 (en) 2008-07-25 2018-06-13 GlaxoSmithKline Biologicals S.A. The tuberculosis rv2386c protein, compositions and uses thereof
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
WO2013090897A1 (en) * 2011-12-15 2013-06-20 The Trustees Of The University Of Pennsylvania Using adaptive immunity to detect drug resistance
CN103467582A (zh) * 2012-06-08 2013-12-25 同济大学 结核杆菌重要抗原的高通量筛选及其在结核病诊断中的应用
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
US10695424B2 (en) 2016-12-07 2020-06-30 Glaxosmithkline Biologicals S.A. Method of making a liposome composition
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
BR112019025193A2 (pt) 2017-05-30 2020-06-23 Glaxosmithkline Biologicals S.A. Métodos de fabricação de um adjuvante lipossomal, de fabricação de um concentrado lipossomal, para a preparação de uma composição imunogênica com adjuvante e para a preparação de uma solução, adjuvante lipossomal, composição imunogênica com adjuvante, e, solução
JP2021504424A (ja) 2017-12-01 2021-02-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
US20220218811A1 (en) * 2019-04-17 2022-07-14 Codiak Biosciences, Inc. Methods of treating tuberculosis
US20220235095A1 (en) 2019-06-05 2022-07-28 Glaxosmithkline Biologicals Sa Saponin purification

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016146A (en) * 1974-12-10 1977-04-05 Biological Developments, Inc. Phenethylamine antigenic conjugates, their preparation, antibodies, and use
PL170980B1 (pl) 1992-06-25 1997-02-28 Smithkline Beecham Biolog Szczepionka PL PL PL PL PL PL PL
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6613881B1 (en) 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
US7087713B2 (en) * 2000-02-25 2006-08-08 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
NZ507378A (en) 1998-04-07 2002-12-20 Corixa Corp Fusion proteins of mycobacterium tuberculosis antigens and their uses
US6291013B1 (en) * 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
WO2001019993A2 (en) 1999-09-17 2001-03-22 University Of Maryland, Baltimore Virulence genes of m. marinum and m. tuberculosis
AU779978B2 (en) 1999-10-07 2005-02-24 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
ES2333579T3 (es) 2000-06-20 2010-02-24 Corixa Corporation Proteinas de fusion de mycobacterium tuberculosis.
AU2002302919A1 (en) 2001-02-22 2002-10-03 Institut Pasteur Comparative mycobacterial geneomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
AU2003213118A1 (en) 2002-02-15 2003-09-09 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
US20030236393A1 (en) * 2002-03-22 2003-12-25 United States Of America Dept Of Vetrans Affairs Virulence genes of M. marinum and M. tuberculosis
US7424370B2 (en) * 2004-02-06 2008-09-09 Council Of Scientific And Industrial Research Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential
PT2426141E (pt) * 2005-04-29 2014-11-25 Glaxosmithkline Biolog Sa Método para prevenção ou tratamento de uma infecção por m. tuberculosis
WO2008007942A1 (en) 2006-07-10 2008-01-17 Het Nederlands Kanker Instituut Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof
MX362698B (es) * 2007-03-02 2019-02-01 Glaxosmithkline Biologicals Sa Metodo novedoso y composiciones.
EP2315834B1 (en) * 2008-07-25 2018-06-13 GlaxoSmithKline Biologicals S.A. The tuberculosis rv2386c protein, compositions and uses thereof
WO2010010178A1 (en) 2008-07-25 2010-01-28 Glaxosmithkline Biologicals S.A The tuberculosis rv2707c protein, compositions and uses thereof
SI2315773T1 (sl) 2008-07-25 2016-12-30 Glaxosmithkline Biologicals S.A. Polipeptidi, polinukleotidi in sestavki za uporabo pri zdravljenju latentne tuberkuloze
PL2421557T3 (pl) 2009-04-24 2019-07-31 Statens Serum Institut Szczepionka przeciwko gruźlicy do zapobiegania reaktywacji
US8367055B2 (en) 2009-05-14 2013-02-05 Wisconsin Alumni Research Foundation Immunogenic compositions against tuberculosis
PL2528621T3 (pl) 2010-01-27 2017-07-31 Glaxosmithkline Biologicals S.A. Zmodyfikowane antygeny gruźlicy

Also Published As

Publication number Publication date
CA2731549C (en) 2018-07-17
CN102164612A (zh) 2011-08-24
MX2011000981A (es) 2011-03-02
BRPI0916705A2 (pt) 2015-11-10
CY1119737T1 (el) 2018-06-27
CO6400198A2 (es) 2012-03-15
US9750794B2 (en) 2017-09-05
NO2315597T3 (uk) 2018-01-20
HUE037121T2 (hu) 2018-08-28
US9315556B2 (en) 2016-04-19
EA201100071A1 (ru) 2011-10-31
EP2315597B1 (en) 2017-08-23
JP5824360B2 (ja) 2015-11-25
SG10201505149WA (en) 2015-07-30
AU2009273133B2 (en) 2014-06-05
PL2315597T3 (pl) 2018-01-31
ES2647321T3 (es) 2017-12-20
US20110223200A1 (en) 2011-09-15
CN102164612B (zh) 2018-01-16
AU2009273133A1 (en) 2010-01-28
WO2010010180A1 (en) 2010-01-28
EA022203B1 (ru) 2015-11-30
KR20160013262A (ko) 2016-02-03
LT2315597T (lt) 2018-02-12
SI2315597T1 (sl) 2017-12-29
EP2315597A1 (en) 2011-05-04
US20160184420A1 (en) 2016-06-30
IL210588A0 (en) 2011-03-31
CA2731549A1 (en) 2010-01-28
PT2315597T (pt) 2017-11-20
KR20110060891A (ko) 2011-06-08
JP2011528897A (ja) 2011-12-01
CN108059660A (zh) 2018-05-22
HRP20171694T1 (hr) 2017-12-15

Similar Documents

Publication Publication Date Title
UA107329C2 (uk) Туберкульозний білок rv2386c, композиція, що його містить, та застосування
UA107180C2 (uk) Туберкульозний білок rv1753c, композиція, що його містить, та застосування
UA107330C2 (uk) Туберкульозний білок rv3616c та його застосування
PH12019500644A1 (en) Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
MX2009010800A (es) Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
AR125326A2 (es) Composiciones de neisseria meningitidis y métodos de las mismas
UA103751C2 (uk) Імуногенний пептид для імунотерапії
WO2012046061A3 (en) Clostridium difficile antigens
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
MX2009010148A (es) Peptidos ciclicos de proteinas receptor-asociadas (rap).
MX2008012748A (es) Un proceso para la concentracion de un polipeptido.
MX360208B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX360211B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX363136B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2011006846A (es) Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv.
NZ703597A (en) Mutant fragments of ospa and methods and uses relating thereto
PH12015501705A1 (en) Methods for producing diketopiperazines and compositions containing diketopiperazines
GB201206070D0 (en) Clostridium difficile antigens
NZ721015A (en) Mutant fragments of ospa and methods and uses relating thereto
PH12020551955A1 (en) Anti-cd63 antibodies, conjugates, and uses thereof
NZ596501A (en) Casb7439 constructs